Sign In
Buy NTLA
$14.75
+1.73 (+13.29%)
At Close: Jun 04, 2026
3 Gene-Editing Stocks With the Potential to Mint Millionaires
05:20am, Wednesday, 13'th Dec 2023
Gene editing stocks have received a lot of attention throughout 2023. The intense focus on gene editing therapies and CRISPR technology is likely only to increase moving forward: The U.S. Food and Dru
Could Intellia Therapeutics Become the Next CRISPR Therapeutics?
06:00am, Tuesday, 12'th Dec 2023
Intellia and CRISPR Therapeutics both work in the field of gene editing. CRISPR Therapeutics just won regulatory approval for its first product, while Intellia recently entered late-stage development
CRISPR Gene Editing: Intellia Vs. Crispr Therapeutics
12:20am, Wednesday, 29'th Nov 2023
Intellia Therapeutics and CRISPR Therapeutics are considered the top two players in the CRISPR space in the next 1 to 3 years. NTLA focuses on in vivo gene editing and has a comprehensive pipeline tar
2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market
05:30am, Tuesday, 28'th Nov 2023
Teladoc Health is roaring ahead on the path to profitability, making gains in EBITDA and free cash flow. One of Intellia Therapeutics' gene-editing candidates is entering late-stage studies, a step cl
CRISPR-Cas9 Gene Editing Is On The Cusp Of Something Big
03:39am, Saturday, 25'th Nov 2023
Gene editing, also known as genome editing, allows scientists to modify the DNA of organisms using biotechnological techniques. CRISPR-Cas9 is the most widely used gene editing technology, known for i
Intellia (NTLA) Rises on EC's Orphan Drug Tag for HAE Candidate
12:47pm, Wednesday, 15'th Nov 2023
The European Commission bestows orphan drug designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema. Stock rises.
Intellia: Soon-To-Be Enrollment Completion Brings About Catalysts In 2024
05:19pm, Tuesday, 14'th Nov 2023
Intellia Therapeutics, Inc. enrollment completion for the phase 2 study using NTLA-2002 for the treatment of hereditary angioedema is expected in Q4 2023; Results expected in 2024. Pending positive fe
Intellia (NTLA) Beats on Q3 Earnings, Provides Pipeline Update
07:31am, Friday, 10'th Nov 2023
Intellia (NTLA) reports mixed third-quarter 2023 results. Management provides developmental and regulatory updates on its key pipeline candidates.
3 Biotech Stocks That Are Betting on the Future of Gene Editing
03:37pm, Thursday, 09'th Nov 2023
The fields of gene editing and gene therapy have been growing since the first draft of the human genome map was finished in 2003. In 2022, gaps in that map were completed.
Intellia Therapeutics, Inc. (NTLA) Q3 2023 Earnings Call Transcript
12:32pm, Thursday, 09'th Nov 2023
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Ian Karp - SVP, IR and Corporate Communications John Leonard - President an
1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years
06:45am, Thursday, 02'nd Nov 2023
The healthcare sector has produced several of the best-performing stocks since World War II. The secret to their outperformance has been their laser-like focus on innovation.
Intellia Therapeutics Will Soon Make Biotech History. Is the Stock a Buy?
07:30am, Saturday, 28'th Oct 2023
Intellia will soon start a phase 3 gene-editing trial, the first of its kind. Succeeding with the trial will not be the last hurdle it needs to overcome.
CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics l
Intellia (NTLA) Focuses on Developing Gene-Editing Therapies
11:18am, Monday, 23'rd Oct 2023
Intellia's (NTLA) in-vivo CRISPR-based gene-edited therapy candidate NTLA-2001 holds potential. Other pipeline candidates are in early-stage development and progressing well.
Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time
05:00am, Saturday, 21'st Oct 2023
Superstar investor Cathie Wood believes in buying innovators when they're down and holding for the long term. Her flagship fund is outperforming the S&P 500 this year.
